SREBF1

Across TCGA pan-cancer cohorts, SREBF1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SREBF1 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SREBF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SREBF1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where SREBF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.271	0.866	.013	8	view →
CCRCC	OS	Median	III,IV	0.689	1.000	.018	4	view →
LSCC	DFS	Tertile	III,IV	0.483	0.879	.032	4	view →
PDAC	OS	Tertile	II,III,IV	0.818	0.215	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SREBF1–LUAD (DFS)

Open the LUAD breakdown →